A $90 million investment plan to expand two of its U.S. facilities was recently announced.
Drug substance development and manufacturing services are provided at the Riverview site.
The expansion of the facility in Kentucky was celebrated by the company with a ceremony on June 25,25.
Increased medical necessity, broader regulatory approvals, and sizable advancements in scientific research and development are driving the growth of the sterile injectables market.
The investment will allow the company to meet the rising demand for both sterile injectables and ADC therapies while enhancing its competitive edge in the market.
The urgent need for us is underscored by the fact that the sterile injection market is projected to exceed $20B by 2028.
"As the market adjusts and preferences shift, we are committed to adapting to meet its current requirements," said Peter DeYoung, Chief Executive Officer.
40 new full-time jobs will be created in the local community by the expansion of the facility.
At the ceremony, Linda Gorton expressed her excitement about the project and the promising opportunities it presents for the city, stating, "Piramal's decision to expand its facility here in Lexington sends a message around the world that Lexington is a great place to do business."
Jim Stephanou, CEO ofIPS-Integrated Project Services, echoed Mayor Gorton's sentiment and said, "IPS is a proud supporter of Piramal's growth over the past five years, providing fit-for-purpose solutions ontransformational projects across India."
Bob Quick, President and CEO of Commerce, said, "We are proud to celebrate this milestone moment with Piramal and excited for its continued growth and success."
The $90M investment in its U.S. facilities represents a significant advancement in its manufacturing capabilities.
There is a company called Piramal pharma solutions.
We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia.
For more information visit:
There is a company called Piramal pharma limited.
The portfolio of differentiated products and services is offered through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries.
For more information, visit:
PPL's minority investment in Yapan Bio is included.
PRnewswire.com's photo caption is "Piramal Pharmaceuticals Expansion."
A leading global Contract Development and Manufacturing Organization is part of the company.
L'un des leaders mondiaux de l'industrie pharmaceutique et du bien-tre, annoncé...
Do not sell or share my information.

Source prnewswire